Core Insights - BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutic products for metabolic diseases by targeting human aging biology [1][3] - The company will present at the Jefferies Global Healthcare Conference in London from November 17-20, 2025 [1][2] Company Overview - BioAge's lead product candidate, BGE-102, is an orally available small-molecule NLRP3 inhibitor aimed at treating obesity and cardiovascular risk factors [3] - A Phase 1 SAD/MAD trial for BGE-102 is currently underway, with initial SAD data expected by the end of the year [3] - The company is also developing long-acting injectable and oral small molecule APJ agonists for obesity [3] - BioAge's preclinical programs utilize insights from its proprietary discovery platform based on human longevity data, targeting key pathways involved in metabolic aging [3]
BioAge Labs to Present at Jefferies Global Healthcare Conference in London